Appropriate target range of INR and predictive factors of recurrent thrombosis and bleeding in patients with venous thromboembolism on warfarin
Open Access
- 2 July 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Abstract
Warfarin is the cornerstone of venous thromboembolism (VTE) treatment. An appropriate international normalized ratio (INR) range of prothrombin time can prevent recurrent VTE and decrease bleeding risk. This study aimed to identify the appropriate INR range for warfarin therapy and evaluate the predictive factors for recurrent VTE and bleeding events. This study included patients diagnosed with VTE and treated with warfarin. We compared three targets of the therapeutic INR range (1.5–2.5, 2.0–3.0, and 2.5–3.5). Among patients with VTE receiving warfarin, no significant differences in VTE recurrence were observed among the three INR targets. Patients with a target INR of 1.5–2.5 had lower bleeding rates than other groups. Smoking was a significant predictive factor for recurrent VTE. Transiently provoked VTE and active cancer were significant risk factors for bleeding, while the target range of INR 1.5–2.5 with good compliance was a protective factor for bleeding. In summary, a target INR of 1.5–2.5 effectively prevented recurrent VTE with minimal bleeding risk in patients taking warfarin. Smoking increases VTE recurrence risk, highlighting the importance of smoking cessation to reduce thrombotic risk. Shorter anticoagulant duration could balance thrombotic and bleeding risks in patients with transiently provoked VTE.Keywords
This publication has 44 references indexed in Scilit:
- Bleeding Risk in Patients with CancerHamostaseologie, 2024
- The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysiseClinicalMedicine, 2023
- Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolismEuropean Journal of Internal Medicine, 2023
- Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTEResearch and Practice in Thrombosis and Haemostasis, 2021
- Antithrombotic Management of Venous ThromboembolismJACC, 2020
- A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with CancerThrombosis and Haemostasis, 2020
- Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolismJournal of Thrombosis and Thrombolysis, 2016
- Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR controlThrombosis Research, 2009
- Venous Thromboembolism According to AgeArchives of internal medicine (1960), 2004
- A Method to Determine the Optimal Intensity of Oral Anticoagulant TherapyThrombosis and Haemostasis, 1993